SN-38

SN-38
Names
	Other names 7-Ethyl-10-hydroxy-camptothecin
Identifiers
CAS Number	86639-52-3 ;
3D model (JSmol)	Interactive image;
ChEBI	CHEBI:8988 ;
ChEMBL	ChEMBL837 ;
ChemSpider	94634 ;
ECHA InfoCard	100.171.154
IUPHAR/BPS	6925;
PubChem CID	104842;
UNII	0H43101T0J ;
CompTox Dashboard (EPA)	DTXSID4040399 ;
	InChI InChI=1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3/t22-/m0/s1 Key: FJHBVJOVLFPMQE-QFIPXVFZSA-N ; InChI=1/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3/t22-/m0/s1 Key: FJHBVJOVLFPMQE-QFIPXVFZBM;
	SMILES O=C\1N4\C(=C/C2=C/1COC(=O)[C@]2(O)CC)c3nc5c(c(c3C4)CC)cc(O)cc5;
Properties
Chemical formula	C22H20N2O5
Molar mass	392.404 g/mol
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

SN-38 is an antineoplastic drug. It is the active metabolite of irinotecan (an analog of camptothecin - a topoisomerase I inhibitor) but has 1000 times more activity than irinotecan itself. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold.^[1]

SN38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1.

The variant of UGT1A1 in ~10% of Caucasians which leads to poor metabolism of SN-38 predicts irinotecan toxicity, as it is then less easily excreted from the body in its SN-38 glucuronide form.^[2]

SN-38 and its glucuronide are lost into the bile and intestines. It can cause the symptoms of diarrhoea and myelosuppression experienced by ~25% of the patients administered irinotecan.

Interactive pathway map

Click on genes, proteins and metabolites below to link to respective articles. ^{[§ 1]}

[[File:

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

|alt=Irinotecan Pathway edit]]

Irinotecan Pathway edit

^ The interactive pathway map can be edited at WikiPathways: "IrinotecanPathway_WP229".

References

^ http://labeling.pfizer.com/ShowLabeling.aspx?id=533
^ O'Dwyer PJ, Catalano RB (October 2006). "Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy". J. Clin. Oncol. 24 (28): 4534–8. doi:10.1200/JCO.2006.07.3031. PMID 17008691.

This oncology article is a stub. You can help Wikipedia by expanding it.

[WikiPathways-3] The interactive pathway map can be edited at WikiPathways: "IrinotecanPathway_WP229".

[1] ttp://labeling.pfizer.com/ShowLabeling.aspx?id=533

[ODwyer2006-2] O'Dwyer PJ, Catalano RB (October 2006). "Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy". J. Clin. Oncol. 24 (28): 4534–8. doi:10.1200/JCO.2006.07.3031. PMID 17008691.

[1]

[2]

[§ 1]

Interactive pathway map

See also

References